Zobrazeno 1 - 10
of 195
pro vyhledávání: '"ALK+"'
Autor:
Muthiah Vaikundaraja Indhuja, Sivasree Kesana, Nikita Mehra, Parathan Karunakaran, Arun Kumar Rajan, Venkatraman Radhakrishnan, Perumal Kalaiyarasi Jayachandran
Publikováno v:
South Asian Journal of Cancer, Vol 13, Iss 02, Pp 121-125 (2024)
Externí odkaz:
https://doaj.org/article/20f8ca09aa0a4cc29d696c0cefb09b6a
Autor:
Grace Chazan, M.B.B.S., BSc, FRACP, Fanny Franchini, BSc, MSc, DPhil, Roma Shah, MPH, Marliese Alexander, BPharm (Hons), MPH, PhD, Ani John, PhD, Maarten IJzerman, BSc, MSc, PhD, Benjamin Solomon, M.B.B.S., PhD, FRACP
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 8, Pp 100662- (2024)
Introduction: ALK–rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use. Little is known about changes in treatment patterns, or how prognostic factors and seq
Externí odkaz:
https://doaj.org/article/3eb06d5d1ed3454a8a2475f9e0119edb
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveSAF-189s is a potent ALK/ROS1 inhibitor that is currently in clinical development for treating advanced ALK+/ROS1+ non-small cell lung cancer (NSCLC). Comprehensive population pharmacokinetics (PopPK) and exposure–response models were deve
Externí odkaz:
https://doaj.org/article/781117d2f18b49b1ad708847a0666c61
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 19-27 (2024)
Alexandria TM Lee,1 Sai-Hong Ignatius Ou1,2 1University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Sai-Hong Ignatius Ou, Division of Hemat
Externí odkaz:
https://doaj.org/article/2546c96c26c048d3bbe7c62697e7dedb
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 659-671 (2023)
María Presa,1 David Vicente,2 Antonio Calles,3 Laura Salinas-Ortega,1 Jaesh Naik,4 Luis F García,5 Javier Soto6 1Health Economics, Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain; 2Medical Oncology Department, Hospital Univers
Externí odkaz:
https://doaj.org/article/19dc736b9da948ba87dcb5b2e01ec069
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 14, Pp 57-62 (2023)
Alexandria TM Lee,1 Saihong Ignatius Ou1,2 1University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Saihong Ignatius Ou, University of Calif
Externí odkaz:
https://doaj.org/article/a4920faea99648adaa4cc549408017c6
Autor:
Minsuk Kwon, Bo mi Ku, Steve Olsen, Sehhoon Park, Martina Lefterova, Justin Odegaard, Hyun‐Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn
Publikováno v:
Cancer Medicine, Vol 11, Iss 15, Pp 2944-2956 (2022)
Abstract Background Patients with ALK‐rearranged non‐small cell lung cancer (ALK+ NSCLC) inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma DNA (cfDNA) next‐generation sequencing (NGS) could predict t
Externí odkaz:
https://doaj.org/article/8eb3dae224764b56b6cda174cd528194
Autor:
Andrew Xiao, Nahid Shahmarvand, Alexandra Nagy, Jyoti Kumar, Jessica Van Ziffle, Patrick Devine, Franklin Huang, Lhara Lezama, Peng Li, Robert S. Ohgami
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma (ALK+ LBCL) is an aggressive and rare subtype of B-cell lymphoma. Patients typically present with advanced clinical stage disease and do not respond to conventional chemotherapy; the med
Externí odkaz:
https://doaj.org/article/03c6998d8089436e9c52ba034407c755
Autor:
Loélia Babin, Alice Darchen, Elie Robert, Zakia Aid, Rosalie Borry, Claire Soudais, Marion Piganeau, Anne De Cian, Carine Giovannangeli, Olivia Bawa, Charlotte Rigaud, Jean-Yves Scoazec, Lucile Couronné, Layla Veleanu, Agata Cieslak, Vahid Asnafi, David Sibon, Laurence Lamant, Fabienne Meggetto, Thomas Mercher, Erika Brunet
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-18 (2022)
Abstract Background Anaplastic large cell lymphoma positive for ALK (ALK+ ALCL) is a rare type of non-Hodgkin lymphoma. This lymphoma is caused by chromosomal translocations involving the anaplastic lymphoma kinase gene (ALK). In this study, we aimed
Externí odkaz:
https://doaj.org/article/a1c4dd48d3b24f998de122fdb6715403
Autor:
Zihua Zou, Xuezhi Hao, Cuiying Zhang, Haojing Li, Guilan Dong, Yumei Peng, Kewei Ma, Ye Guo, Li Shan, Yan Zhang, Li Liang, Yangchun Gu, Puyuan Xing, Junling Li
Publikováno v:
Thoracic Cancer, Vol 13, Iss 1, Pp 107-116 (2022)
Abstract Background There is limited data on the clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in a real‐world setting for Chinese patients with advanced ALK+ NSCLC. M
Externí odkaz:
https://doaj.org/article/87d7d152cdcc469aafecd2b00aea35e7